Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse
View original at globenewswire.comCommuniqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes at…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Dupixent has been approved in Japan as the first targeted medication for treatment of adults with bullous pemphigoid
60% confidenceDupilumab has been studied in more than 60 clinical studies involving more than 12,000 patients with various chronic diseases partly due to type 2 inflammation
60% confidenceDupixent is a fully human monoclonal antibody that inhibits IL-4 and IL-13 pathway signaling and is not an immunosuppressant
60% confidenceMore than four times as many patients treated with Dupixent achieved sustained disease remission compared to placebo (18% vs. 4%; p=0.0250) at week 36
60% confidenceMore than 1.4 million patients are treated with Dupixent worldwide
60% confidenceDupixent has received regulatory authorizations in more than 60 countries for one or more indications
60% confidenceBullous pemphigoid is the seventh approved indication for Dupixent in Japan
60% confidenceTreatment-related adverse events occurred in 26% of patients treated with Dupixent and in 15% of patients on placebo, with conjunctivitis being the most frequently reported at 4%
60% confidenceDupixent's development program has shown significant clinical benefit and reduction in type 2 inflammation in phase 3 studies, establishing that IL-4 and IL-13 are two key and central factors of type 2 inflammation
60% confidence